These advanced biocompatible nanocarriers might have high therapeutic value in the treatment of diabetes because they are formed by the production of cycloborates and make use of the glucose/H2O2 dual responsiveness to enable a quicker release of insulin, as shown in Figure 17. The gene discussed is INS; the disease is diabetes mellitus.